Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lisheng Kong

Vascular Surgery Ventura, CA Medical Doctor

NPI 1891764775 CMS profile 176855

100 N Brent St, Suite 201, Ventura, CA 93003

Open in the dashboard

General payments

$13,811

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisheng Kong of Ventura, CA is reported in the CMS Open Payments database as having received $13,811 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,149 28
2024 General $1,562 25
2023 General $2,439 63
2022 General $988 28
2021 General $2,621 55
2020 General $192 8
2019 General $860 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisheng Kong
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Lisheng Kong were reported at $5,149. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Lisheng Kong Vascular Surgery median Middle half National median
2019 $860 $796 $226–$2,363 $163
2020 $192 $348 $118–$1,110 $114
2021 $2,621 $471 $158–$1,421 $132
2022 $988 $725 $222–$2,183 $149
2023 $2,439 $836 $257–$2,440 $160
2024 $1,562 $909 $252–$2,619 $164
2025 $5,149 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $3,750 1 payment
  2. Medtronic, Inc. $3,475 80 payments
  3. Philips Electronics North America Corporation $1,419 41 payments
  4. Imperative Care, INc $992 10 payments
  5. Endologix, Inc. $614 5 payments
  6. Inari Medical, Inc. $600 9 payments
  7. Boston Scientific Corporation $437 13 payments
  8. Reflow Medical Inc $427 3 payments
  9. W. L. Gore & Associates, Inc. $364 5 payments
  10. Janssen Pharmaceuticals, Inc $279 14 payments
  11. Other $1,453 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,034 215 payments
  2. Long term medical supply or device loan $3,750 1 payment
  3. Travel and Lodging $950 10 payments
  4. Education $76 2 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $3,750 1 payment
  2. Ellipsys $1,328 16 payments
  3. PRODIGY CATHETER $981 9 payments
  4. CONCERTOTM $678 9 payments
  5. CT THROMBECTOMY SYSTEM KIT $600 9 payments
  6. FLOWTRIEVER CATHETER, S $600 9 payments
  7. XARELTO $371 15 payments
  8. Ovation $359 1 payment
  9. Abre $349 16 payments
  10. (6577) Visions 014 $301 10 payments
  11. Other $5,313 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

518

Median for Vascular Surgery: 122

Drug cost

$133,891

Median for Vascular Surgery: $14,135

Branded share of claims

60.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 52 $69,385
Xarelto Rivaroxaban Brand 47 $59,563
Clopidogrel Clopidogrel Bisulfate Brand 179 $2,316
Cilostazol Generic 75 $1,182
Atorvastatin Calcium Generic 71 $554
Cephalexin Generic 46 $549
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 13 $188
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 24 $142
Famotidine Generic 11 $13

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$1,091,133

Medicare's payments for the services billed

Medicare patients

987

Average age 75

Services billed

5,173

516 women, 471 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 46%
Chronic kidney disease 43%
Ischemic heart disease 39%
Heart failure 26%
Atrial fibrillation 26%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record